Healthcare
Amicus Therapeutics, Inc.(FOLD)
Live Price
Offline$14.49
+0.00% today
Window Change
+153.77%
Window
Jun 23, 2025 โ Apr 27, 2026
- Market Cap
- $4.55B
- Revenue Growth
- +20.0%
- EPS Growth
- +51.2%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 213 bars ยท Jun 23, 2025 โ Apr 27, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Amicus Therapeutics, Inc. (FOLD) is a Healthcare stock with a market cap of $4.55B and listed on NASDAQ. The stock last traded around $14.49 and up 153.8% across the available one-year price window (Jun 23, 2025 โ Apr 27, 2026). Baseline metrics include revenue growth of +20.0%, EPS growth of +51.2%, a dividend yield of 0.0%. What stands out right now is revenue +20.0%, EPS +51.2%, free cash flow +179.7% with operating margin 5.2% and ROIC -645.7%. Valuation sits in the middle of the pack at price/sales 7.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FOLD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.0% vs +7.6% peer median
Operating Margin
Below sector median
+5.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.0% and EPS at +51.2%, with operating margin around 5.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.7% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 20, 2026 | -86.0% | +0.1% | +0.2% | +0.6% |
2025 Nov 4, 2025 | +41.7% | +2.2% | +3.7% | +8.8% |
2025 Jul 31, 2025 | -50.0% | +5.5% | +13.4% | +27.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
FOLD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
FOLD Max Drawdown
-10.04%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FOLD and SPY.
Company Overview
Amicus Therapeutics, Inc.
NASDAQ Global Market
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
- Leadership
- Bradley L. Campbell
- IPO Date
- May 31, 2007
- Employees
- 499
- Street Address
- 3675 Market Street
- Mailing
- Philadelphia, PA, 19104
- Region
- Philadelphia, PA, US
- Reporting Currency
- USD
- Investor Line
- 215 921 7600
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 89.6
- Price/Sales
- 7.2
- Price/Book
- 16.3
Growth
- Revenue
- +20.0%
- EPS
- +51.2%
- Free Cash Flow
- +179.7%
Profitability
- Gross Margin
- 87.9%
- Operating Margin
- 5.2%
- Net Margin
- -4.3%
- ROE
- -12.0%
- ROIC
- -645.7%
Balance Sheet
- Debt/Equity
- 1.76
- Current Ratio
- 2.84
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.